Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion
Dan Cohen(Tel Aviv Sourasky Medical Center), Chava Perry(Tel Aviv University), Ofrat Beyar‐Katz(Rambam Health Care Campus), Einat Even‐Sapir(Tel Aviv University)
European Journal of Nuclear Medicine and Molecular Imaging
February 11, 2022
Cited by 16
Related Papers
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
|Blood Advances|2021|170
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
|Transplantation and Cellular Therapy|2021|164
Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
|Cancer Research|2018|103
Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia
|Leukemia|2019|69
Novel Approaches to Acute Myeloid Leukemia Immunotherapy
|Clinical Cancer Research|2018|63